Enovix (NASDAQ:ENVX - Get Free Report) had its price target decreased by equities research analysts at B. Riley Financial from $17.00 to $10.00 in a note issued to investors on Monday,MarketScreener reports. The firm currently has a "buy" rating on the stock. B. Riley Financial's price objective would indicate a potential upside of 96.70% from the company's previous close.
Other analysts also recently issued reports about the company. TD Cowen cut their target price on Enovix from $15.00 to $7.50 and set a "hold" rating on the stock in a research note on Thursday. JPMorgan Chase & Co. dropped their price objective on Enovix from $12.00 to $10.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 12th. Northland Securities set a $16.00 price objective on Enovix in a report on Monday, November 17th. Oppenheimer reissued an "outperform" rating on shares of Enovix in a research report on Thursday. Finally, Cantor Fitzgerald reduced their price target on shares of Enovix from $30.00 to $25.00 and set an "overweight" rating for the company in a research note on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Enovix has a consensus rating of "Moderate Buy" and an average target price of $14.95.
View Our Latest Research Report on ENVX
Enovix Trading Down 3.5%
NASDAQ:ENVX opened at $5.08 on Monday. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -6.71 and a beta of 2.15. The company has a quick ratio of 8.13, a current ratio of 8.34 and a debt-to-equity ratio of 1.90. The company's 50 day moving average price is $7.10 and its 200-day moving average price is $8.87. Enovix has a 52 week low of $5.03 and a 52 week high of $16.49.
Institutional Trading of Enovix
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Enovix by 10.9% during the fourth quarter. Vanguard Group Inc. now owns 17,760,708 shares of the company's stock valued at $129,831,000 after purchasing an additional 1,747,145 shares in the last quarter. Millennium Management LLC raised its position in shares of Enovix by 1,038.9% during the 3rd quarter. Millennium Management LLC now owns 1,476,879 shares of the company's stock valued at $14,724,000 after purchasing an additional 1,347,200 shares during the period. Two Sigma Investments LP lifted its stake in shares of Enovix by 9,197.1% during the 3rd quarter. Two Sigma Investments LP now owns 1,200,997 shares of the company's stock valued at $11,974,000 after buying an additional 1,188,079 shares in the last quarter. Barclays PLC boosted its holdings in Enovix by 263.1% in the 4th quarter. Barclays PLC now owns 1,551,941 shares of the company's stock worth $11,345,000 after buying an additional 1,124,480 shares during the period. Finally, Electron Capital Partners LLC increased its stake in Enovix by 13.8% in the 3rd quarter. Electron Capital Partners LLC now owns 8,038,396 shares of the company's stock worth $80,143,000 after buying an additional 972,103 shares in the last quarter. Hedge funds and other institutional investors own 50.92% of the company's stock.
About Enovix
(
Get Free Report)
Enovix Corporation NASDAQ: ENVX develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.
Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enovix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.
While Enovix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.